Omeros’ Omidria Revenues Grow 71 Percent

August 11, 2017: By Jon Swedien

OMEROSRevenues from Omidria grew 71 percent in Q2-2017 compared with Q2-2016, Seattle-based Omeros reported Aug. 8.

Omidria’s revenues during the quarter totaled $17.2 million, which marked a 40 percent increase over the drug’s revenues in Q1-2017, Omeros said. All of Omeros’ Q2-2017 revenues came from Omidria sales.

Omeros said units shipped by wholesalers in Q2-2017 increased 113 percent over Q2-2016 and 34 percent over Q1-2017.

Launched in April 2015, Omidria is intended for use during cataract surgery to maintain pupil size by preventing intraoperative miosis and to reduce postoperative ocular pain. It is a combination of a mydriatic agent and a nonsteroidal anti-inflammatory agent that is added to irrigation solution used during IOL procedures.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022